Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicities Lasting, durable responses observed out to 18 months in adult participants Expected FDA Meeting in Q4 2025 Management to Host Webcast and Conference Call Today at 8:30 A.M. ET… Read More..

- Earnings call scheduled for Tuesday, September 30, 2025, at 8:30 a.m. ET - Over $43 million in debt converted, reducing De-SPAC liabilities by more than 80% - Stockholders’ Equity is up over $43 million from Year End 2024 - Third correspondent clearing customer signed to onboard - Extended contract… Read More..

TAMPA, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear Holdings” or the “Company”) today announced the appointment of Mr. Steven Carlson to the Board of Directors as an Independent Board member. AtlasClear Holdings reported today that Mr. Steven Carlson has accepted its invitation to… Read More..